No. Taking Super Zhewitra together with another PDE5 inhibitor (e.g., sildenafil, tadalafil) can cause dangerously low blood pressure and should be avoided.
Vardenafil generally begins to work within 30 minutes, while dapoxetine reaches peak plasma levels within 1-2 hours. Most men experience the combined benefit within an hour when the pill is taken on an empty stomach.
If blood pressure is well-controlled and you are not using nitrates, the medication may be used with caution. Uncontrolled hypertension is a relative contraindication; discuss your cardiovascular status with a prescriber before starting.
Yes. Fixed-dose combinations are often marketed under different brand names or may not be available at all outside the UK. Imprint codes, tablet color, and packaging can vary by region.
Moderate alcohol consumption is generally tolerated, but excessive intake can worsen hypotension and diminish erectile response. It is advisable to limit alcohol to a standard drink or less.
Neither vardenafil nor dapoxetine directly alter testosterone or other sex hormones. Their actions are limited to vascular and neural pathways involved in erection and ejaculation.
Seek emergency medical care immediately. Priapism lasting more than four hours can cause permanent tissue damage if not treated promptly.
Alpha-blockers and certain calcium-channel blockers may have additive blood-pressure-lowering effects when combined with vardenafil. Your prescriber may adjust the antihypertensive dose or monitor you more closely.
Coverage depends on clinical indication, NHS formulary status, and local prescribing policies. Because the fixed-dose combination is not specifically approved, it may require a specialist prescription and may not be routinely reimbursed.
The tablet is designed for whole-tablet ingestion. Splitting or crushing may affect the release profile and should not be done unless specifically instructed by a pharmacist.
Super Zhewitra is a combined medication that contains two active ingredients: vardenafil and dapoxetine. Vardenafil belongs to the class of phosphodiesterase-5 (PDE5) inhibitors and is used to treat erectile dysfunction (ED). Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) indicated for premature ejaculation (PE). The product is supplied as a pill in a 20 mg/60 mg strength. In the United Kingdom, the medication would be classified as prescription-only (POM) and would fall under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA). As of the latest publicly available information, a fixed-dose combination of vardenafil and dapoxetine is not approved by the MHRA; therefore, any use should be under the direct supervision of a qualified prescriber.
The two mechanisms act on separate physiological pathways-vascular erectile response and central ejaculatory control-so the combination aims to address both conditions simultaneously.
Super Zhewitra is intended for adult men who experience both erectile dysfunction and premature ejaculation. In the UK, the individual components have the following approved indications:
When used together, the combination may provide coordinated management of the two co-existing sexual dysfunctions. However, because the fixed-dose product is not formally approved, its use is considered off-label and must be individualized by a prescriber.
The combination of a PDE5 inhibitor with a short-acting SSRI has been explored in clinical research to assess synergistic benefits for men with concurrent ED and PE. Small-scale trials have reported improvements in both erection quality and ejaculatory latency compared with either agent alone. These studies are not yet sufficient to secure regulatory approval for a combined formulation.
Disclaimer: Off-label use of Super Zhewitra requires careful medical supervision. Health professionals must weigh potential benefits against risks and monitor patients closely.
These effects are usually mild, self-limiting, and resolve without medical intervention.
Patients should seek urgent medical care if any of these serious symptoms arise.
Major Interactions
Nitrates (e.g., glyceryl trinitrate, isosorbide dinitrate): co-administration can cause profound hypotension.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): can raise vardenafil plasma levels, increasing risk of side effects.
Serotonergic drugs (e.g., other SSRIs, MAO inhibitors, tramadol, linezolid): raise the risk of serotonin syndrome with dapoxetine.
Moderate Interactions
Alpha-blockers (e.g., tamsulosin, doxazosin): may cause additive blood-pressure lowering; monitor closely.
Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce vardenafil effectiveness.
Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and recreational drugs to their prescriber.
Note: Because Super Zhewitra is a fixed-dose product, dose adjustments are limited to the available 20 mg/60 mg strength. If a lower dose of either component is required, a prescriber may opt for separate tablets of vardenafil and dapoxetine.
This article provides educational information about Super Zhewitra and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
